益盛药业(002566) - 2016 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥6,169,141.64, a decrease of 60.64% year-on-year[8]. - Operating revenue for the reporting period was ¥233,125,254.22, reflecting a slight increase of 0.80% compared to the same period last year[8]. - Basic earnings per share were ¥0.02, a decrease of 60.00% year-on-year[8]. - The weighted average return on net assets was 0.35%, down 0.53% from the previous year[8]. - The estimated net profit attributable to shareholders for 2016 is expected to range from RMB 12,002.7 million to RMB 14,185 million, representing a growth of 10% to 30% compared to RMB 10,911.5 million in 2015[24]. - The company’s net profit is expected to be positive and not a turnaround situation for the fiscal year 2016[24]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,751,026,389.59, an increase of 4.45% compared to the end of the previous year[8]. - Prepayments decreased by 82.78% compared to the beginning of the period, mainly due to the settlement of previous red ginseng procurement payments[16]. - Construction in progress increased by 79.24% compared to the beginning of the period, primarily due to increased investment in ginseng processing projects[16]. - Other non-current assets increased by 112.40% compared to the beginning of the period, mainly due to an increase in prepaid project and equipment payments[16]. - Deferred income tax assets decreased by 33.72% compared to the beginning of the period, mainly due to a reduction in deductible losses recognized during the period[16]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥47,248,964.71, down 113.66% compared to the previous year[8]. - Cash received from other operating activities decreased by 34.68% compared to the same period last year, mainly due to a decrease in inter-company loans[17]. - Cash paid for purchasing goods and accepting services decreased by 51.98% compared to the same period last year, mainly due to a reduction in the procurement of red ginseng[17]. - Cash received from investment income decreased by 86.42% compared to the same period last year, mainly due to a decrease in the redemption of financial products[17]. - Cash received from minority shareholders' capital increase increased by 7734.19% compared to the same period last year, mainly due to capital increases from minority shareholders of subsidiaries[18]. Shareholder Information - The total number of shareholders at the end of the reporting period was 25,186[12]. - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[12]. - The company plans to increase its shareholding amounting to no less than RMB 10 million through the Shenzhen Stock Exchange trading system[23]. - The chairman, Zhang Yisheng, confirmed the commitment to not reduce shareholdings during the specified period[23]. Government and Non-Recurring Items - The company received government subsidies amounting to ¥23,230,235.50, which are closely related to its business operations[9]. - Non-recurring gains and losses for the year-to-date totaled ¥18,359,311.08[9]. - Operating income from non-operating activities increased by 315.58% compared to the same period last year, primarily due to an increase in government subsidies[17]. Risks and Compliance - The company has identified potential risks related to the price volatility of fresh ginseng, which may affect the valuation of certain inventory[25]. - There are no instances of non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[27]. - The company has not engaged in any external guarantee violations during the reporting period[26]. - The company has complied with all relevant regulations regarding insider trading and sensitive period transactions[23]. - No research, communication, or interview activities were conducted during the reporting period[28]. - The company is preparing for potential inventory impairment based on current market prices of fresh ginseng[25].